The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $65.09

Today's change+5.54 +9.30%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $65.09

Today's change+5.54 +9.30%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Isis Pharmaceuticals Inc Hits New 52-week High

Isis Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$5.54 or 9.30% to (U.S.)$65.09 and setting a new 52-week high. Over the last five days, shares have gained 4.44% and are currently 3.02% off of the 52-week high. Shares have outperformed the S&P 500 by 52.77% during the last year.

Key company metrics

  • Open(U.S.) $63.05
  • Previous close(U.S.) $59.55
  • High(U.S.) $67.12
  • Low(U.S.) $60.85
  • Bid / Ask-- / --
  • YTD % change+63.38%
  • Volume10,086,936
  • Average volume (10-day)4,243,399
  • Average volume (1-month)2,581,431
  • Average volume (3-month)2,458,331
  • 52-week range(U.S.) $22.25 to (U.S.) $67.12
  • Beta1.59
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.81
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-54.98%

Isis Pharmaceuticals Inc has a net profit margin of -54.98%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue44572842
Total other revenue--------
Total revenue44572842
Gross profit-17-2-25-15
Total cost of revenue61595357
Total operating expense66645862
Selling / general / administrative4445
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income-21-7-30-20
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-25-11-34-24
Income after tax-27-12-31-24
Income tax, total11-21
Net income-27-12-31-24
Total adjustments to net income--------
Net income before extra. items-27-12-31-24
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-27-12-31-24
Inc. avail. to common incl. extra. items-27-12-31-24
Diluted net income-27-12-31-24
Dilution adjustment----00
Diluted weighted average shares118118117116
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.10-0.27-0.21
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.10-0.27-0.21